Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine

Cancer Letters

Volumn 263, Issue 2, 2008, Pages 291-301

  Correale, Pierpaolo ^b   Vecchio, Maria Teresa Del ^a   Renieri, Tommaso ^a   Genova, Giuseppa Di ^a   Placa, Marco La ^b   Remondo, Cinzia ^b   Savellini, Gianni Gori ^a   Terrosi, Chiara ^a   Zurbriggen, Rinaldo ^c   Amacker, Mario ^c   Francini, Guido ^b   Cusi, Maria Grazia ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b Medical Oncology Section   (Italy)

^c Pevion Biotech Ltd   (Switzerland)

Author keywords

Angiogenesis; Cancer vaccine; Immunotherapy; IRIV; PTH rP

Indexed keywords

CANCER VACCINE; IMMUNE RECONSTITUTED INFLUENZA VIROSOME; INFLUENZA VACCINE; PARATHYROID HORMONE RELATED PROTEIN; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VIROSOME VACCINE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG EFFECT; DRUG FORMULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INFLUENZA A VIRUS; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PARATHYROID HORMONE-RELATED PROTEIN; VACCINES, SUBUNIT; VACCINES, VIROSOME;

ANIMALIA; MUS;

EID: 41649084521     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.018     Document Type: Article

References (25)

1. Yin J.J., Selander K., Chirgwin J.M., et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103 (1999) 197-206
2. Siclari V.A., Guise T.A., and Chirgwin J.M. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev. 25 4 (2006) 621-633 Review
3. Guise T.A. Parathyroid hormone-related protein and bone metastases. Cancer 80 (1997) 1572-1580
4. Guise T.A., Mohammad K.S., Clines G., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res. 12 20 Pt. 2 (2006) 6213s-6216s Review
5. Yoneda T. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur. J. Cancer 34 (1998) 240-245
6. Correale P., Micheli L., Del Vecchio M.T., et al. A parathyroid-hormone-related protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Br. J. Cancer 85 (2001) 1722-1730
7. Correale P., Cusi M.G., Sabatino M., et al. Tumor associated antigen (TAA) specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA plasmids delivered by influenza virosomes. Eur. J. Cancer 37 (2001) 2097-2103
8. Francini G., Scardino A., Kosmatopoulos K., et al. High affinity HLA-A(*)02.01 peptides from parathyroid-hormone related protein generate in vitro and in vivo antitumor CTL response without autoimmune side effects. J. Immunol. 169 (2002) 4840-4849
9. Zurbriggen R., Novak-Hofer I., Seelig A., and Gluck R. IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization. Prog. Lipid Res. 39 (2000) 3-18
10. Cusi M.G., Terrosi C., Gori Savellini G., et al. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine 22 (2004) 735-739
11. Cusi M.G. Applications of influenza virosomes as a delivery system. Hum. Vaccine 2 1 (2006) 1-7
12. Scardino A., Correale P., Firat H., et al. In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse. Br. J. Cancer 89 (2003) 199-205
13. Glück R., Moser C., and Metcalfe I.C. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin. Biol. Ther. 4 (2004) 1139-1145
14. Schumacher R., Adamina M., Zurbrigen R., et al. Infuenza virosomes enhance class I restricted CTL induction through CD4+T cell activation. Vaccine 22 (2004) 714-723
15. Bungener L., Huckriede A., De mare A., et al. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23 (2005) 1232-1241
16. Amacker M., Egler O., Kammer A.R., et al. Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells. Int. Immunol. 17 (2005) 695-704
17. Schumacher R., Amacker M., Neuhaus D., et al. Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26-35) peptide encapsulated into virosomes in vitro. Vaccine 23 (2005) 5572-5582
18. Parker K.C., Bednarek M.A., and Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152 (1994) 163-175
19. Pascolo S., Bervas N., Ure J.M., et al. HLA-A(*)02.01-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLAA(*) 02.01 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 185 (1997) 2043-2051
20. Workman P., Twentyman P., Balkwill F., et al. United Kingdom co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the welfare of animals in experimental neoplasia. (second ed). Br. J. Cancer 77 (1998) 1-10
21. Schneck J.P., Slansky J.E., O'Herrin S.M., and Greten T.F. Dimer Assay: Monitoring antigen-specific T cells using MHC-Ig dimers. In: Coligan J., Kruisbeek A.M., Margulies D., Shevach E.M., and Strober S.E. (Eds). Current Protocols in Immunology Inc. (2000), John Wiley & Sons, New York, NY 17.2.1-17.2.17
22. Sercarz E.E., Lehmann P.V., Ametani A., et al. Dominance and crypticity of T cell antigenic determinants. Ann. Rev. Immunol. 11 (1993) 729-766
23. Gulley J.L., Madan R.A., and Arlen P.M. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 25 (2007) B89-B96
24. Teramoto K., Kontani K., Fujita T., Ozaki Y., Sawai S., Tezuka N., Fujino S., Itoh Y., Taguchi O., Kannagi R., and Ogasawara K. Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA. Cancer Immunol. Immunother. 56 3 (2007) 331-342
25. Kowalczyk D.W., Wlazlo A.P., Giles-Davis W., et al. Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack. Cancer Ther. 10 (2003) 870-878